In 1990, it was demonstrated that increasing the concentration of sodium chloride facilitated coprecipitation of Bence Jones proteins
with human Tamm-Horsfall glycoprotein in vitro .
As a gauge of patients' response to therapy, serial UPEP studies combined with densitometric scanning are commonly used to measure changes in Bence Jones protein
excretion over time.
No M protein, Bence Jones protein
, accumulation of gallium, or abnormal cells in bone marrow were detected, which suggested that the plasmacytoma had not developed into multiple myeloma.
A century later, work by Korngold and Lipari (2) characterized Bence Jones proteins
and showed that they reacted with those found in myeloma.
A systemic workup for multiple myeloma included a bone marrow biopsy, bone scan, quantitative immunoglobulin assay, and measurements of hematocrit, white blood cells, blood urea, serum creatinine, serum electrolytes, serum calcium, and Bence Jones proteins
CT and measurements of serum immunoglobulin and urinary Bence Jones protein
levels may be useful in detecting recurrence or conversion to multiple myeloma.
Our objectives, in a prospective study with consecutive samples received for SPEP, were to evaluate (a) whether the addition of serum FLCs identified extra patients with monoclonal gammopathies at the time of a first request for SPEP; (b) whether serum FLCs could replace urinalysis for Bence Jones protein
(BJP); and (c) the cost and quality implications of routinely measuring serum FLCs.
The first laboratory test for a protein cancer marker, the Bence Jones protein
in urine, was described in 1847.
Tests for Bence Jones protein
in the urine and for serum myeloma protein were negative.
Bence Jones protein
with cryoglobulin properties is rare.